Cited by 756Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and TreatmentsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Open access

Meyers, Paul A., Schwartz, Cindy L., Krailo, Mark D., Healey, John H., Bernstein, Mark L., Betcher, Donna, Ferguson, William S., Gebhardt, Mark C., Goorin, Allen M., Harris, Michael, Kleinerman, Eugenie, Link, Michael P., Nadel, Helen, Nieder, Michael, Siegal, Gene P., Weiner, Michael A., Wells, Robert J., Womer, Richard B., Grier, Holcombe E.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2008.14.0095

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma. To determine whether the addition of muramyl tripeptide (MTP) to chemotherapy enhances event-free survival (EFS) and overall survival in newly diagnosed patients with osteosarcoma. Patients and Methods: Six hundred sixty-two patients with osteosarcoma without clinically detectable metastatic disease and whose disease was considered resectable received one of four prospectively randomized treatments. All patients received identical cumulative doses of cisplatin, doxorubicin, and methotrexate and underwent definitive surgical resection of primary tumor. Patients were randomly assigned to receive or not to receive ifosfamide and/or MTP in a 2 × 2 factorial design. The primary end points for analysis were EFS and overall survival. Results: In the current analysis, there was no evidence of interaction, and we were able to examine each intervention separately. The chemotherapy regimens resulted in similar EFS and overall survival. There was a trend toward better EFS with the addition of MTP (P = .08). The addition of MTP to chemotherapy improved 6-year overall survival from 70% to 78% (P = .03). The hazard ratio for overall survival with the addition of MTP was 0.71 (95% CI, 0.52 to 0.96). Conclusion: The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma. The addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2008.14.0095

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Principles and Practice of Pediatric Oncology
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-8-636_3 · Cited by 2,034
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,203
Self-citation
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Meyers, P. A., Schwartz, C. L., Krailo, M., Kleinerman, E. S., Betcher, D. L., Bernstein, M. L., Conrad, E. U., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.031 · Cited by 717
Self-citation
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A. G., Lane, J. M., Marcove, R. C., Applewhite, A., Vlamis, V., & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 675
Self-citation
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643
Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery
Rosen, G., Marcove, R. C., Caparros, B., Nirenberg, A., Kosloff, C., & Huvos, A. G. (1979) · Cancer · doi:10.1002/1097-0142(197906)43:6 · Cited by 584
Interim analysis: The alpha spending function approach
DeMets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 565
Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup
Souhami, R. L., Craft, A. W., van der Eijken, J. W., Nooij, M. A., Spooner, D. A., Bramwell, V. H. C., Wierzbicki, R. F., MALCOLM, A. J., Kirkpatrick, A., Uscinska, B., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02307-6 · Cited by 381

Flagged first, then by citations

Show all 20 references

Sorted by citations

Items 101–200 of 756

Mifamurtide
Frampton, J. E. (2010) · Pediatric Drugs · doi:10.2165/11204910-000000000-00000 · Cited by 118
The value of research collaborations and consortia in rare cancers
Blay, J., Coindre, J., Ducimetière, F., & Ray-Coquard, I. L. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00388-5 · Cited by 115
Whatʼs New in Musculoskeletal Oncology
Lewis, V. O. (2009) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.i.00375 · Cited by 112
Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications
Zhu, T., Han, J., Liu, Y., Cai, Z., Sun, W. Y., Hua, Y., & Xu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907550 · Cited by 113
Chemical Design of Both a Glutathione-Sensitive Dimeric Drug Guest and a Glucose-Derived Nanocarrier Host to Achieve Enhanced Osteosarcoma Lung Metastatic Anticancer Selectivity
Su, L., Li, R., Khan, S. A., Clanton, R., Zhang, F., Lin, Y., Song, Y. H., Wang, H., Fan, J., Hernandez, S., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b11462 · Cited by 108
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
Pignochino, Y., Dell’Aglio, C., Basiricò, M., Capozzi, F., Soster, M., Marchiò, S., Bruno, S., Gammaitoni, L., Sangiolo, D., Torchiaro, E., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2293 · Cited by 107
Pediatric Cancer Immunotherapy: Opportunities and Challenges
Wedekind, M. F., Denton, N. L., Chen, C., & Cripe, T. P. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0297-x · Cited by 113
Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal
Li, S., Sun, W. Y., Wang, H., Zuo, D., Hua, Y., & Cai, Z. (2015) · Tumor Biology · doi:10.1007/s13277-015-3181-0 · Cited by 104
Harnessing the antitumor potential of macrophages for cancer immunotherapy
Long, K. B., & Beatty, G. L. (2013) · OncoImmunology · doi:10.4161/onci.26860 · Cited by 103
The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis
Endo‐Munoz, L., Evdokiou, A., & Saunders, N. A. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.07.003 · Cited by 108
International Collaboration is Feasible in Trials for Rare Conditions: The EURAMOS Experience
Marina, N. M., Bielack, S., Whelan, J. S., Smeland, S., Krailo, M., Sydes, M. R., Butterfaß‐Bahloul, T., Calaminus, G., & Bernstein, M. L. (2009) · Cancer treatment and research · doi:10.1007/978-1-4419-0284-9_18 · Cited by 102
Self-citation
Osteosarcoma: improvement in survival limited to high-grade patients only
Jawad, M. U., Cheung, M. C., Clarke, J., Koniaris, L. G., & Scully, S. P. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0923-7 · Cited by 102
Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway
Lü, Y., Sun, Y., Zhu, J., Yu, L., Jiang, X., Zhang, J., Dong, X., Ma, B., & Zhang, Q. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0031-6 · Cited by 98
Primary malignant bone tumors—recent developments
Hameed, M., & Dorfman, H. D. (2011) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2011.02.002 · Cited by 101
Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ
Pahl, J. H. W., Kwappenberg, K. M. C., Varypataki, E. M., Santos, S. J., Kuijjer, M. L., Mohamed, S., Wijnen, J., van Tol, M. J. D., Cleton-Jansen, A., Egeler, R. M., et al. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-27 · Cited by 101
Frontline treatment of localized osteosarcoma without methotrexate
Daw, N. C., Neel, M. D., Rao, B. N., Billups, C. A., Wu, J., Jenkins, J. J., Quintana, J. A., Luchtman‐Jones, L., Milena Villarroel, C., & Santana, V. M. (2011) · Cancer · doi:10.1002/cncr.25715 · Cited by 99
Emerging drugs for high-grade osteosarcoma
Hattinger, C. M., Pasello, M., Ferrari, S., Picci, P., & Serra, M. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.505603 · Cited by 99
Vitamin D–dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma
Bruns, H., Büttner, M., Fabri, M., Mougiakakos, D., Bittenbring, J. T., Hoffmann, M. H., Beier, F., Pasemann, S., Jitschin, R., Hofmann, A. D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3230 · Cited by 99
Sarcomas of Soft Tissue and Bone
Ferrari, A., Dirksen, U., & Bielack, S. (2016) · Progress in tumor research · doi:10.1159/000447083 · Cited by 96
Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells
Buddingh, E. P., Schilham, M. W., Ruslan, S. E. N., Berghuis, D., Szuhai, K., Suurmond, J., Taminiau, A. H. M., Gelderblom, H. A. J., Egeler, R. M., Serra, M., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0965-3 · Cited by 95
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Park, J. A., & Cheung, N.-K. V. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01012-y · Cited by 88
Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group
Schwartz, C. L., Wexler, L. H., Krailo, M., Teot, L. A., Devidas, M., Steinherz, L. J., Goorin, A. M., Gebhardt, M. C., Healey, J. H., Sato, J. K., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25753 · Cited by 94
Self-citation
The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis
Zhang, B., Zhang, Y., Li, J., Lu, X., Lu, X., & Zhang, Y. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-1576-0 · Cited by 95
Osteosarcoma: Evolution of Treatment Paradigms
Jaffe, N., Puri, A., & Gelderblom, H. (2013) · Sarcoma · doi:10.1155/2013/203531 · Cited by 93
Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
Regan, D. P., Chow, L., Das, S., Haines, L., Palmer, E., Kurihara, J. N., Coy, J. W., Mathias, A., Thamm, D. H., Gustafson, D. L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2105 · Cited by 92
Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective
Benjamin, R. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_1 · Cited by 92
PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas
Bertucci, F., Finetti, P., Perrot, D., Leroux, A., Collin, F., Cesne, A. L., Coindre, J., Blay, J., Birnbaum, D., & Mamessier, É. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1278100 · Cited by 91
Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression
Fan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90
Prognostic factors in pulmonary metastasized high‐grade osteosarcoma
Buddingh, E. P., Anninga, J., Versteegh, M. I. M., Taminiau, A. H. M., Egeler, R. M., van Rijswijk, C. S. P., Hogendoorn, P. C. W., Lankester, A. C., & Gelderblom, H. A. J. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22293 · Cited by 90
Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression
Zhu, L., McManus, M. M., & Hughes, D. P. M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00230 · Cited by 90
A tumor microenvironment-based prognostic index for osteosarcoma
Wu, C., Gong, S., Duan, Y., Deng, C., Kallendrusch, S., Berninghausen, L. K., Osterhoff, G., & Schopow, N. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00917-3 · Cited by 94
UK Guidelines for the Management of Bone Sarcomas
Grimer, R. J., Athanasou, N. A., Gerrand, C., Judson, I. R., Lewis, I. J., Morland, B. J., Peake, D., Seddon, B. M., & Whelan, J. S. (2010) · Sarcoma · doi:10.1155/2010/317462 · Cited by 87
SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT–receptor complex
Zhao, S.-J., Jiang, Y.-Q., Xu, N.-W., Li, Q., Zhang, Q., Wang, S.-Y., Li, J., Wang, Y.-H., Zhang, Y., Jiang, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.403 · Cited by 89
Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors
Green, D. M., Kun, L. E., Matthay, K. K., Meadows, A. T., Meyer, W. H., Meyers, P. A., Spunt, S. L., Robison, L. L., & Hudson, M. M. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24487 · Cited by 92
Self-citation
Circular RNA hsa-circ-0016347 promotes proliferation, invasion and metastasis of osteosarcoma cells
Jin, H., Jin, X., Zhang, H., & Wang, W. (2017) · Oncotarget · doi:10.18632/oncotarget.16104 · Cited by 84
Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma
Deng, C., Xu, Y., Fu, J., Zhu, X., Chen, H., Xu, H., Wang, G., Song, Y., Song, G., Lu, J., et al. (2020) · Cancer Science · doi:10.1111/cas.14398 · Cited by 82
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
(2012) · Annals of Oncology · doi:10.1093/annonc/mds254 · Cited by 84
Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
Luo, Z.-W., Liu, P.-P., Wang, Z.-X., Chen, C.-Y., & Xie, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586580 · Cited by 89
Multiple supervised residual network for osteosarcoma segmentation in CT images
Zhang, R., Huang, L., Xia, W., Zhang, B., Qiu, B., & Gao, X. Q. (2018) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2018.01.006 · Cited by 83
Origin and Therapies of Osteosarcoma
Moukengué, B., Lallier, M., Marchandet, L., Baud’huin, M., Verrecchia, F., Ory, B., & Lamoureux, F. (2022) · Cancers · doi:10.3390/cancers14143503 · Cited by 93
BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line
Wang, L., Park, P., Zhang, H., Marca, F. L., Claeson, A. A., Valdivia, J. M., & Lin, C.-Y. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.5.14372 · Cited by 83
Surgical Technique: Computer-generated Custom Jigs Improve Accuracy of Wide Resection of Bone Tumors
Khan, F. A., Lipman, J. D., Pearle, A. D., Boland, P. J., & Healey, J. H. (2013) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-012-2769-6 · Cited by 83
Self-citation
IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis
Gross, A. C., Cam, H., Phelps, D. A., Saraf, A. J., Bid, H. K., Cam, M., London, C. A., Winget, S. A., Arnold, M. A., Brandolini, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99791 · Cited by 82
Genome-wide analyses on high-grade osteosarcoma: Making sense of a genomically most unstable tumor
Kuijjer, M. L., Hogendoorn, P. C. W., & Cleton-Jansen, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28124 · Cited by 80
Pediatric Malignant Bone Tumors: A Review and Update on Current Challenges, and Emerging Drug Targets
Jackson, T. M., Bittman, M. E., & Granowetter, L. (2016) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2016.04.002 · Cited by 82
Novel therapeutic agents for osteosarcoma
O’Day, K., & Gorlick, R. G. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.7 · Cited by 81
Wnt/β-catenin pathway in bone cancers
Tian, J., He, H., & Lei, G. (2014) · Tumor Biology · doi:10.1007/s13277-014-2433-8 · Cited by 80
MSFCN-multiple supervised fully convolutional networks for the osteosarcoma segmentation of CT images
Huang, L., Xia, W., Zhang, Q., Qiu, B., & Gao, X. (2017) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2017.02.013 · Cited by 80
Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma
van Oosterwijk, J. G., Anninga, J., Gelderblom, H. A. J., Cleton-Jansen, A., & Bovée, J. V. M. G. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.07.012 · Cited by 81
Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2020) · Cancers · doi:10.3390/cancers12071758 · Cited by 82
Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation
Kansara, M., Leong, H. S., Lin, D., Popkiss, S., Pang, P., Garsed, D. W., Walkley, C. R., Cullinane, C. M., Ellul, J., Haynes, N. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70559 · Cited by 77
Choosing The Right Animal Model for Renal Cancer Research
Sobczuk, P., Brodziak, A., Khan, M. I., Chhabra, S., Fiedorowicz, M., Wełniak-Kamińska, M., Synoradzki, K. J., Bartnik, E., Cudnoch‐Jędrzejewska, A., & Czarnecka, A. M. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100745 · Cited by 81
Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma
Abdeen, A. R., Chou, A. J., Healey, J. H., Khanna, C., Osborne, T. S., Hewitt, S. M., Kim, M., Wang, D., Moody, K. M., & Gorlick, R. G. (2009) · Cancer · doi:10.1002/cncr.24562 · Cited by 77
Self-citation
Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma
Chawla, S. P., Chua, V. S., Fernandez, L., Quon, D. V. K., Saralou, A., Blackwelder, W. C., Hall, F. L., & Gordon, E. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.126 · Cited by 77
Rexin-G, a targeted genetic medicine for cancer
Gordon, E. M., & Hall, F. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.481666 · Cited by 77
Notch Signaling is Associated with ALDH Activity and an Aggressive Metastatic Phenotype in Murine Osteosarcoma Cells
Mu, X., Isaac, C. E., Greco, N., Huard, J., & Weiss, K. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00143 · Cited by 77
Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma
Wang, Z., Wang, Z., Li, B., Wang, S., Chen, T., & Ye, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01114 · Cited by 77
Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments
Anderson, P. M., Meyers, P. A., Kleinerman, E. S., Venkatakrishnan, K., Hughes, D. P. M., Herzog, C. E., Huh, W. W., Sutphin, R. M., Vyas, Y. M., Shen, V., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24686 · Cited by 75
Self-citation
Long Non-Coding RNA TUG1 Promotes Proliferation and Inhibits Apoptosis of Osteosarcoma Cells by Sponging miR-132-3p and Upregulating SOX4 Expression
Li, G., Liu, K., & Du, X. (2018) · Yonsei Medical Journal · doi:10.3349/ymj.2018.59.2.226 · Cited by 74
Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma
Himoudi, N., Wallace, R., Parsley, K. L., Gilmour, K., Barrie, A.-U., Howe, K., Dong, R., Sebire, N. J., Michalski, A., Thrasher, A. J., et al. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0795-1 · Cited by 74
Cross Talk from Pets to People: Translational Osteosarcoma Treatments
Withrow, S. J., & Wilkins, R. M. (2010) · ILAR Journal · doi:10.1093/ilar.51.3.208 · Cited by 73
Natural products as lead compounds in drug discovery
Khazir, J., Mir, B. A., Mir, S. A., & Cowan, D. A. (2013) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2013.798314 · Cited by 73
Current concepts on the surgical and medical management of osteosarcoma
Siegel, H. J., & Pressey, J. G. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.8.1257 · Cited by 71
Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities
Sun, C. X., Daniel, P. M., Bradshaw, G., Shi, H., Loi, M., Chew, N. J., Parackal, S., Tsui, V., Liang, Y., Koptyra, M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.007 · Cited by 68
Bone sarcomas: Overview of management, with a focus on surgical treatment considerations
Lietman, S. A., & Joyce, M. (2010) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.77.s1.02 · Cited by 69
Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma)
Anderson, P. M., Kopp, L. M., Anderson, N. R., Cornelius, K., Herzog, C. E., Hughes, D. P. M., & Huh, W. W. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.11.1703 · Cited by 68
Long Noncoding RNA XIST Promotes Osteosarcoma Progression by Targeting Ras-Related Protein RAP2B via miR-320b
Gongyi, L., Miao, J., & Zhang, X. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x14920318811721 · Cited by 67
Managing sarcoma: where have we come from and where are we going?
Bleloch, J., Ballim, R. D., Kimani, S., Parkes, J., Panieri, E., Willmer, T., & Prince, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017728927 · Cited by 69
Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers
Yang, J., Wang, X., Wang, B., Park, K., Wooley, K. L., & Zhang, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114525 · Cited by 67
Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality
Yu, L., Zhang, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871076 · Cited by 68
Immunotherapy of Childhood Sarcomas
Roberts, S. S., Chou, A. J., & Cheung, N. V. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00181 · Cited by 65
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis
Berghuis, D., Schilham, M. W., Vos, H. I., Santos, S. J., Kloeß, S., Buddingh, E. P., Egeler, R. M., Hogendoorn, P. C. W., & Lankester, A. C. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-8 · Cited by 66
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1
Palmerini, E., Agostinelli, C., Picci, P., Pileri, S. A., Marafioti, T., Lollini, P., Scotlandi, K., Longhi, A., Benassi, M. S., & Ferrari, S. M. (2017) · Oncotarget · doi:10.18632/oncotarget.22912 · Cited by 66
Therapeutic Targets for Bone and Soft-Tissue Sarcomas
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010170 · Cited by 66
Strategies for the targeted delivery of therapeutics for osteosarcoma
Hughes, D. P. M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903280422 · Cited by 63
Surgical treatment of pulmonary metastases in pediatric solid tumors
Heaton, T. E., & Davidoff, A. M. (2016) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2016.09.001 · Cited by 63
Drugs in early clinical development for the treatment of osteosarcoma
Heymann, M., Brown, H. K., & Heymann, D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1237503 · Cited by 65
Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease
Harrison, D. J., & Schwartz, C. L. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0464-2 · Cited by 63
Self-citation
Current Treatment Considerations for Osteosarcoma Metastatic at Presentation
Tsukamoto, S., Errani, C., Angelini, A., & Mavrogenis, A. F. (2020) · Orthopedics · doi:10.3928/01477447-20200721-05 · Cited by 59
Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas
Nathenson, M. J., Conley, A. P., & Sausville, E. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0025 · Cited by 61
UK guidelines for the management of bone sarcomas
Gerrand, C., Amary, F. M., Anwar, H. A., Brennan, B. M. D., Dileo, P., Kalkat, M. S., McCabe, M. G., McCullough, A. L., Parry, M., Patel, A., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02868-4 · Cited by 69
Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Biermann, J. S., Hirbe, A. C., Ahlawat, S., Bernthal, N. M., Binitie, O. T., Boles, S. G., Brigman, B. E., Callan, A. K., Cipriano, C. A., Cranmer, L. D., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0017 · Cited by 67
Of dogs and men: Comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma
Rankin, K. S., Starkey, M., Lunec, J., Gerrand, C., Murphy, S., & Biswas, S. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23341 · Cited by 62
Sarcoma Immunotherapy: Past Approaches and Future Directions
D’Angelo, S. P., Tap, W. D., Schwartz, G. K., & Carvajal, R. D. (2014) · Sarcoma · doi:10.1155/2014/391967 · Cited by 62
Historical Perspective on the Introduction and Use of Chemotherapy for the Treatment of Osteosarcoma
Jaffe, N. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_1 · Cited by 61
Sarcomas of Bone
Anderson, M. E., Randall, R. L., Springfield, D. S., & Gebhardt, M. C. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00092-8 · Cited by 59
Self-citation
Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma
Meyers, P. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_11 · Cited by 61
Self-citation
Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma
Lu, B.-J., WANG, Y.-Q., WEI, X.-J., Rong, L., Dong, W., YAN, C.-M., WANG, D.-J., & Sun, J. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.772 · Cited by 60
Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma
Moore, C. E., Eslin, D. E., Levy, A., Roberson, J. R., Giusti, V., & Sutphin, R. M. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22673 · Cited by 60
Sarcomas of the head and neck region
Shellenberger, T. D., & Sturgis, E. M. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0020-8 · Cited by 60
Osteosarcoma: The Same Old Drugs or More?
Bielack, S., Marina, N. M., Ferrari, S., Helman, L. J., Smeland, S., Whelan, J. S., & Reaman, G. H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1108 · Cited by 60
Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma
Yu, D. X., Kahen, E., Cubitt, C. L., McGuire, J., Kreahling, J. M., Lee, J., Altiok, S., Lynch, C. C., Sullivan, D. M., & Reed, D. R. (2015) · Scientific Reports · doi:10.1038/srep16991 · Cited by 59
What Are the Factors That Affect Survival and Relapse After Local Recurrence of Osteosarcoma?
Takeuchi, A., Lewis, V. O., Satcher, R. L., Moon, B. S., & Lin, P. P. (2014) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-014-3759-7 · Cited by 59
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy
Navid, F., Santana, V. M., Neel, M. D., McCarville, M. B., Shulkin, B. L., Wu, J., Billups, C. A., Mao, S., Daryani, V. M., Stewart, C. F., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30841 · Cited by 59
Aggressive treatment of non-metastatic osteosarcoma improves health-related quality of life in children and adolescents
Hinds, P. S., Gattuso, J. S., Billups, C. A., West, N. K., Wu, J., Rivera, C., Quintana, J. A., Milena Villarroel, C., & Daw, N. C. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.020 · Cited by 58
The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats
Zabielska-Koczywąs, K. A., & Lechowski, R. (2017) · Molecules · doi:10.3390/molecules22122167 · Cited by 58
Bone sarcomas in the immunotherapy era
Heymann, M., Schiavone, K., & Heymann, D. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14999 · Cited by 60
Identification of possible reductants in the aqueous leaf extract of mangrove plant Rhizophora apiculata for the fabrication and cytotoxicity of silver nanoparticles against human osteosarcoma MG-63 cells
Wen, X., Wang, Q., Dai, T., Shao, J., Wu, X., Jiang, Z., Jacob, J. A., & Jiang, C. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111252 · Cited by 59
Role of Tumor-Associated Macrophages in Sarcomas
Fujiwara, T., Healey, J. H., Ogura, K., Kondo, H., Kondo, H., Hata, T., Tazawa, H., Nakata, E., Kunisada, T., Fujiwara, T., et al. (2021) · Cancers · doi:10.3390/cancers13051086 · Cited by 61
Self-citation
Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group
Spraker‐Perlman, H. L., Barkauskas, D. A., Krailo, M., Meyers, P. A., Schwartz, C. L., Doski, J. J., Gorlick, R. G., Janeway, K. A., & Isakoff, M. S. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27444 · Cited by 56
Self-citation

Authors: Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., Kleinerman, E., Link, M. P., Nadel, H., Nieder, M., Siegal, G. P., Weiner, M. A., Wells, R. J., Womer, R. B., & Grier, H. E.
Affiliations: Children's Oncology Group (US)
ORCID: Meyers, Paul A.
Schwartz, Cindy L.
Krailo, Mark D.
Healey, John H.
Bernstein, Mark L.
Ferguson, William S.
Kleinerman, Eugenie
Nadel, Helen
Siegal, Gene P.
Womer, Richard B.
Grier, Holcombe E.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-02-01
Volume: 26
Issue: 4
Pages: 633-638
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2008.14.0095
OpenAlex: W2103405666
Cited by: 752
References: 20
Citations by year: 2026: 21 · 2025: 30 · 2024: 30 · 2023: 31 · 2022: 40 · 2021: 51 · 2020: 70 · 2019: 39 · 2018: 38 · 2017: 55 · 2016: 49 · 2015: 50 · 2014: 57 · 2013: 46 · 2012: 36
FWCI: 33.48
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: Children’s Oncology Group
National Institutes of Health (CA98543)
National Cancer Institute (U10CA098543, CA-98543)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: osteosarcoma, muramyl tripeptide, ifosfamide, cisplatin, doxorubicin, methotrexate, event-free survival, overall survival, pediatric cancer chemotherapy, immunomodulatory therapy, surgical resection
MeSH terms: Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Child, Preschool, Cisplatin, Doxorubicin, Female, Humans, Ifosfamide, Infant, Lung Neoplasms, Male, Methotrexate, Neoplasm Recurrence, Local, Osteosarcoma, Survival Rate, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks